Wegovy Injection Site Reactions That Won't Go Away: When to Worry and What to Do

How Common Are Injection Site Reactions With Wegovy?

Injection site reactions rank among the most frequently reported local adverse events for subcutaneous semaglutide, though they occur far less often than gastrointestinal side effects. The pooled STEP trial program provides the clearest incidence data available.

In the STEP 1 trial (N=1,961), injection site reactions occurred in 3.2% of participants receiving semaglutide 2.4 mg weekly compared to 2.8% on placebo, a modest but real difference [1]. The reactions were predominantly mild (Grade 1) and self-limiting. Across all four STEP trials, the discontinuation rate specifically attributed to injection site reactions was below 0.2% [2].

The FDA prescribing information for Wegovy groups these events into erythema, pain, swelling, induration, and pruritus at the injection site [3]. What the label does not spell out is the timeline. Most prescribers expect resolution within a few days. The question that brings patients to search engines is what happens when it does not.

A post-marketing pharmacovigilance review in the FDA Adverse Event Reporting System (FAERS) captured reports of injection site nodules, lipodystrophy, and prolonged induration that persisted beyond the 7-day mark [4]. These cases, while uncommon, represent a distinct clinical pattern from the transient soreness most patients experience.

Why Wegovy Causes Injection Site Reactions in the First Place

The mechanism behind subcutaneous injection site reactions involves two overlapping processes: mechanical tissue disruption and a local immune response to the injected formulation. Understanding both explains why some reactions linger.

Semaglutide is formulated as a clear solution with a pH around 7.4 and delivered via a prefilled pen with a thin-gauge needle (typically 29-31 gauge). The act of depositing 0.25 to 2.4 mg of drug solution into the subcutaneous fat layer causes immediate mechanical irritation. That part resolves quickly. The more relevant driver for persistent reactions is the local histamine release and immune cell recruitment triggered by the formulation excipients and the peptide itself [5].

Semaglutide contains a C-18 fatty diacid side chain that enables albumin binding and extends its half-life to approximately 7 days. This same lipophilic modification means the drug forms a subcutaneous depot at the injection site. In most patients, the depot disperses gradually as semaglutide binds circulating albumin and enters systemic distribution. In a subset of patients, the depot provokes a localized foreign-body-type response with macrophage and lymphocyte infiltration [6].

Temperature matters. Injecting a pen straight from the refrigerator (2-8°C) into tissue at 37°C creates a thermal gradient that can increase local vasoconstriction and slow drug dispersion. The Wegovy prescribing information recommends allowing the pen to reach room temperature before use, but many patients skip this step [3]. That single omission correlates with higher rates of injection site pain and induration in clinical practice observations.

Defining "Persistent": What Normal Resolution Looks Like vs. What Doesn't

A typical Wegovy injection site reaction follows a predictable arc. Redness and mild swelling appear within minutes to hours. Pain peaks at 6-12 hours. By 48-72 hours, visible signs fade. By day 5, the site feels normal.

Persistent reactions break this pattern in specific ways. The American Academy of Allergy, Asthma & Immunology classifies injection site reactions by immunologic mechanism, and the distinction matters for management [7]:

Immediate reactions (Type I, IgE-mediated) appear within 60 minutes: urticaria, wheal-and-flare, sometimes with localized angioedema. These are uncommon with semaglutide and typically resolve within 24 hours with antihistamine treatment. If they recur with each injection and expand in severity, they signal true drug allergy.

Delayed reactions (Type IV, T-cell-mediated) are the more likely culprit behind persistent injection site problems with Wegovy. These appear 48-72 hours post-injection and present as firm, indurated, sometimes pruritic plaques that can persist for 2-4 weeks. A case series in the Journal of Clinical Endocrinology & Metabolism documented delayed-type hypersensitivity to GLP-1 receptor agonists presenting as persistent subcutaneous nodules that resolved only after drug discontinuation or switch to an alternative agent [8].

Lipohypertrophy, a localized increase in subcutaneous fat tissue, represents a third mechanism. Well-documented in the insulin literature, lipohypertrophy develops from repeated injection into the same site. A systematic review published in Diabetes Care found lipohypertrophy prevalence of 28-44% among insulin users who did not rotate sites adequately [9]. The same tissue remodeling process applies to any repeatedly injected subcutaneous drug, including weekly semaglutide.

The 7-Day / 14-Day / 28-Day Decision Framework

Not every persistent reaction demands the same response. Clinical decision-making improves when organized around three time thresholds.

Still present at 7 days: This exceeds normal resolution but may still represent slow drug depot absorption, particularly in patients with higher body fat percentage at the injection site or those who injected cold medication. Practical response: warm compresses for 10-15 minutes twice daily, verify injection technique and temperature preparation, and document the site for comparison.

Still present at 14 days: A reaction lasting two full weeks is unlikely to be simple mechanical irritation. Consider delayed-type hypersensitivity (firm induration with or without pruritus), early lipohypertrophy (painless, rubbery mass), or injection into superficial dermis rather than subcutaneous tissue. Practical response: clinical evaluation including visual inspection and palpation, consider marking the area to track expansion or contraction, and review injection depth and angle.

Still present at 28 days: A month-old injection site reaction requires active investigation. Options include dermatologic referral for possible biopsy of persistent nodules, drug allergy evaluation if reactions recur at multiple sites, and discussion of whether to continue Wegovy, switch to an alternative GLP-1 receptor agonist, or modify the injection protocol.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "When we see injection site reactions that persist beyond two weeks with semaglutide, the first thing we reassess is technique. In my experience, about half of persistent reactions trace back to injection depth, site selection, or cold-temperature injection rather than true drug intolerance."

Evidence-Based Management of Persistent Injection Site Reactions

Managing a Wegovy injection site reaction that will not resolve requires a layered approach. Start with the simplest interventions before escalating.

Temperature and technique optimization form the foundation. Allow the Wegovy pen to sit at room temperature for 30 minutes before injecting. Pinch the skin to ensure adequate subcutaneous depth. Inject slowly over 5-10 seconds rather than rapid bolus delivery. A randomized study of injection technique variables in subcutaneous drug delivery showed that slow injection speed reduced pain scores by 31% and induration diameter by 22% compared to rapid injection [10].

Strict site rotation is non-negotiable for persistent reactors. The Endocrine Society clinical practice guidelines on obesity pharmacotherapy recommend rotating among abdomen, anterior thigh, and posterior upper arm, using a systematic pattern that avoids re-injecting within 2 inches of a prior site for at least 4 weeks [11]. A simple approach: divide the abdomen into four quadrants and rotate clockwise weekly, skipping any quadrant with a palpable residual nodule.

Topical corticosteroids (triamcinolone 0.1% cream or betamethasone valerate 0.1%) applied to the affected site twice daily for 5-7 days can reduce inflammation in delayed-type hypersensitivity reactions. This recommendation is extrapolated from dermatologic management of subcutaneous drug reactions reviewed in the Journal of the American Academy of Dermatology [12]. Oral antihistamines (cetirizine 10 mg daily) may help with pruritus but do not accelerate resolution of indurated nodules.

Ice application immediately after injection (10 minutes, with a cloth barrier) can reduce initial inflammation. Warm compresses (15 minutes, twice daily) starting 24 hours later promote drug depot absorption and improve blood flow to the area. The sequence matters. Ice first, warmth later.

When Persistent Reactions Signal Something More Serious

Some patterns of non-resolving injection site reactions require immediate clinical attention rather than watchful waiting. Recognizing the red flags prevents delays in diagnosis.

Expanding erythema with warmth and fever may indicate secondary bacterial infection (cellulitis) at the injection site. The CDC guidelines on skin and soft tissue infections note that any break in the skin, including injection punctures, creates a portal of entry for Staphylococcus aureus and Streptococcus pyogenes [13]. Cellulitis requires oral or parenteral antibiotics, not topical corticosteroids.

Purulent drainage or fluctuance suggests abscess formation. This is rare with thin-gauge prefilled pen injections but has been reported in FAERS for subcutaneous GLP-1 receptor agonists, particularly in immunocompromised patients or those reusing pen needles [4].

Progressive induration with satellite lesions (smaller nodules appearing around the primary site) raises concern for granulomatous foreign body reaction. A histopathologic study of subcutaneous drug depot reactions published in the American Journal of Dermatopathology showed that granulomatous responses to injected peptide formulations can mimic sarcoidosis on biopsy and may require intralesional corticosteroid injection for resolution [14].

Systemic symptoms accompanying local reactions, including generalized urticaria, angioedema distant from the injection site, dyspnea, or hypotension, indicate anaphylaxis or systemic drug allergy. The STEP trials excluded patients with known hypersensitivity to semaglutide, but post-marketing anaphylaxis reports exist in the FDA safety database and carry a black-triangle pharmacovigilance signal [3].

Switching Strategies When Injection Site Reactions Persist Despite Optimization

For patients who have optimized technique, rotated sites systematically, and still experience persistent injection site reactions with every Wegovy dose, the clinical question becomes whether to switch agents or delivery modalities.

Within-class switch to oral semaglutide (Rybelsus). By eliminating subcutaneous injection entirely, oral semaglutide removes the local reaction variable. The OASIS 1 trial demonstrated that oral semaglutide 50 mg produced 15.1% mean weight loss at 68 weeks, comparable to subcutaneous dosing [15]. The trade-off is strict fasting requirements (30 minutes before food or other medications) and potentially higher gastrointestinal side effect rates during titration.

Cross-class switch to tirzepatide (Zepbound). Tirzepatide uses a different formulation and injection device. While injection site reactions also occur with tirzepatide (SURMOUNT-1 reported a 7.0% incidence), the immunologic profile differs because tirzepatide is a dual GIP/GLP-1 receptor agonist with a distinct acylation chemistry [16]. Patients with presumed delayed-type hypersensitivity to semaglutide specifically may tolerate tirzepatide without cross-reactivity.

The American Association of Clinical Endocrinology 2023 obesity treatment algorithm recommends trialing an alternative GLP-1 receptor agonist before discontinuing the drug class entirely when side effects are site-specific rather than systemic [17].

Dr. Ania Jastreboff, director of the Yale Obesity Research Center and co-investigator on the SURMOUNT trial program, has stated: "Injection site reactions to one GLP-1 receptor agonist do not predict reactions to another. The formulation excipients, the device, and the molecule itself all differ. We routinely trial a switch before concluding that a patient cannot tolerate the class."

Documenting and Reporting Persistent Reactions

Patients experiencing injection site reactions lasting beyond 14 days should photograph the site at injection, day 3, day 7, and day 14 for clinical documentation. Measure erythema diameter in centimeters. Note texture (soft vs. indurated vs. fluctuant) and associated symptoms (pain, pruritus, warmth).

Healthcare providers can submit persistent or unusual injection site reactions to FDA MedWatch as voluntary adverse event reports. These reports feed the FAERS database and contribute to post-marketing signal detection [4]. Novo Nordisk maintains a manufacturer pharmacovigilance line for Wegovy-specific reports.

The minimum clinically relevant data to include: patient age and sex, Wegovy dose at time of reaction, injection site location, time to onset, duration, description of the lesion, and whether the reaction recurred at a different site with subsequent injections.